Skip to content

Madrigal Pharmaceuticals

US · MDGL #1355 by market cap Listed 2016
379.10 -17.64 -4.45%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 35 in the most recent period (2026/Q3).
  • Total institutional ownership fell 1.5 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
106.26% -1.49pp
Institutions
544 +35
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund53.97%
Hedge Fund41.11%
Private Company5.74%
Individual/Insider5.20%
Public Company3.19%
Government Pension Fund0.98%
Sovereign Wealth Fund0.93%
Insurance Company0.19%

Top holders as of 2026-11-06

Baker Bros. Advisors LP 8.78% · 2.04M sh
RTW Investments, LP 8.58% · 1.99M sh
Janus Henderson Group plc 8.33% · 1.94M sh
Avoro Capital Advisors LLC 7.89% · 1.83M sh
Paulson & Co. Inc. 5.77% · 1.34M sh
BlackRock 5.33% · 1.24M sh
Vanguard Capital Management, LLC 3.64% · 846.64K sh
Wellington Management Group 3.55% · 825.71K sh
Vanguard Portfolio Management, LLC 3.28% · 761.02K sh
SQN, LLC 2.82% · 655.54K sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 30 buys · 20 sells

NameRoleStake
Rebecca Taub Founder, Senior Scientific & Medical Advisor and Director 1.90%
Frederick Craves Former Lead Independent Director 1.58%
Paul Friedman Former Director 0.74%
William Sibold Chief Executive Officer 0.66%
Brian Lynch Former Senior Vice President 0.11%
Richard Levy Independent Director 0.09%
David Soergel Chief Medical Officer 0.04%
Robert Waltermire Chief Pharmaceutical Development Officer 0.02%
Raymond Cheong Independent Director 0.02%
James Daly Independent Director 0.01%
Julian Baker Independent Chairperson 0.02%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-05 Baker Bros. Advisors LP -- Open Market Acquisition +91,806 $366.99–396.61
2026-11-05 Shannon Kelley Executive Vice President Open Market Disposition -1,077 $400.00
2026-09-27 Paul Friedman Former Director Intent to Sell (Form 144) -50,000 $516.56
2026-09-10 William Sibold Chief Executive Officer Automatic Disposition -5,221 $533.09–546.38
2026-09-08 William Sibold Chief Executive Officer Open Market Disposition -6,362 $527.88–542.55
2026-08-16 Shannon Kelley Executive Vice President Open Market Disposition -664 $514.97
2026-08-14 John Reed Director Other Acquisition +647 --
2026-08-14 John Reed Director Other Derivative Acquisition +1,078 $507.56
2026-07-19 William Sibold Chief Executive Officer Derivative Exercise and Sale -2,500 $542.75–555.05
2026-07-16 William Sibold Chief Executive Officer Derivative Exercise and Retained +47,500 --
2026-06-16 Julian Baker Independent Chairperson Other Acquisition +454 --
2026-06-16 Julian Baker Independent Chairperson Other Derivative Acquisition +766 $499.86
2026-06-16 Jacqualyn Fouse Independent Director Other Acquisition +454 --
2026-06-16 Jacqualyn Fouse Independent Director Other Derivative Acquisition +766 $499.86
2026-06-16 Richard Levy Independent Director Other Acquisition +454 --
2026-06-16 Richard Levy Independent Director Other Derivative Acquisition +766 $499.86
2026-06-16 Rebecca Taub Founder, Senior Scientific & Medical Advisor and Director Other Acquisition +454 --
2026-06-16 Rebecca Taub Founder, Senior Scientific & Medical Advisor and Director Other Derivative Acquisition +766 $499.86
2026-06-16 James Daly Independent Director Other Acquisition +454 --
2026-06-16 James Daly Independent Director Other Derivative Acquisition +766 $499.86

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Madrigal Pharmaceuticals discussion 0 comments

Add a comment